	Des Atouts		Date
Acadia Pharmaceuticals	USD 1.33B	105.22M	2025-09
Alnylam Pharmaceuticals	USD 4.85B	285.64M	2025-09
Amgen	USD 90.14B	2.24B	2025-09
Biogen	USD 29.44B	232M	2025-12
BioMarin Pharmaceutical	USD 7.61B	158.53M	2025-09
Cytokinetics	USD 1.44B	210.92M	2025-09
Daiichi Sankyo	JPY 3.82T	252.52B	2025-12
Gilead Sciences	USD 58.53B	2.81B	2025-09
Incyte	USD 6.33B	509M	2025-09
Ionis Pharmaceuticals	USD 3.03B	47.96M	2025-09
Ironwood Pharmaceuticals	USD 396.06M	53.12M	2025-09
Novartis	USD 107.29B	2.89B	2025-09
Pfizer	USD 208.73B	2.64B	2025-09
PTC Therapeutics	USD 2.64B	9.54M	2025-09
Roche Holding	CHF 100.7B	5.94B	2025-12
Sarepta Therapeutics	USD 3.49B	186.38M	2025-09
TG Therapeutics	USD 1.03B	322.41M	2025-09
Ultragenyx Pharmaceutical	USD 1.19B	115.82M	2025-09
Vertex Pharmaceuticals	USD 24.86B	825.6M	2025-09
Xencor	USD 868.81M	10.61M	2025-09

PTC Therapeutics Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Feb 2026.